Small Molecule Screen Identifies Pyrimethamine as an Inhibitor of NRF2-driven Esophageal Hyperplasia
Authors: Paiboonrungruang Chorlada , Xiong Zhaohui , Lamson David , Li Yahui , Bowman Brittany , Chembo Julius , Huang Caizhi , Li Jianying , Livingston Eric W. , Frank Jon E. , Chen Vivian , Li Yong , Weissman Bernard , Yuan Hong , Williams Kevin P. , Major M. Ben , Chen Xiaoxin 
Published: December 2022

Objective

NRF2 is a master transcription factor that regulates the stress response. NRF2 is frequently mutated and activated in human esophageal squamous cell carcinoma (ESCC), which drives resistance to chemotherapy and radiation therapy. Therefore, a great need exists for NRF2 inhibitors for targeted therapy of NRF2highESCC.

Design

We performed high-throughput screening of two compound libraries from which hit compounds were further validated in human ESCC cells and a genetically modified mouse model. The mechanism of action of one compound was explored by biochemical assays.

Results

Using high-throughput screening of two small molecule compound libraries, we identified 11 hit compounds as potential NRF2 inhibitors with minimal cytotoxicity at specified concentrations. We then validated two of these compounds, pyrimethamine and mitoxantrone, by demonstrating their dose- and time-dependent inhibitory effects on the expression of NRF2 and its target genes in twoNRF2Muthuman ESCC cells (KYSE70 and KYSE180). RNAseq and qPCR confirmed the suppression of global NRF2 signaling by these two compounds. Mechanistically, pyrimethamine reduced NRF2 half-life by promoting NRF2 ubiquitination and degradation in KYSE70 and KYSE180 cells. Expression of anNrf2E79Qallele in mouse esophageal epithelium (Sox2CreER;LSL-Nrf2E79Q/+) resulted in an NRF2highphenotype, which included squamous hyperplasia, hyperkeratinization, and hyperactive glycolysis. Treatment with pyrimethamine (30mg/kg/day,p.o.) suppressed the NRF2highesophageal phenotype with no observed toxicity.

Conclusion

We have identified and validated pyrimethamine as an NRF2 inhibitor that may be rapidly tested in the clinic as a radiation and chemotherapy sensitizer for NRF2highESCC.

What is already known on this topic – summarise the state of scientific knowledge on this subject before you did your study and why this study needed to be done

Mutational activation of the NRF2 transcription factor drives ESCC progression and therapeutic resistance. Targeted therapies to block NRF2 have not yet been realized, despite great needs.

What this study adds – summarise what we now know as a result of this study that we did not know before

A screen of >35,000 small molecules identified eleven potential NRF2 inhibitors. Pyrimethamine and mitoxantrone were validated to inhibit the expression of NRF2 and NQO1 in human ESCC cells in both dose- and time-dependent manners.

Pyrimethamine enhanced NRF2 protein ubiquitination and degradation, resulting a decreased half-life.

A genetically modified mouse model was established to express theNrf2E79Qmutant allele in the mouse esophageal epithelium upon tamoxifen induction. Pyrimethamine suppressed the NRF2highesophageal phenotype induced by the mutant allele.

How this study might affect research, practice or policy – summarise the implications of this study

As an FDA-approved drug, Pyrimethamine has the potential for immediate translation to a clinical trial on NRF2highESCC in humans.

Further exploration of its mechanisms of action may lead to more potent NRF2 inhibitors for future use.